* Alzamend Neuro Inc reported a quarterly adjusted loss of 38 cents per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of -90 cents. The mean expectation of two analysts for the quarter was for a loss of 32 cents per share. Wall Street expected results to range from -41 cents to -24 cents per share.
* Reported revenue was zero; analysts expected zero.
* Alzamend Neuro Inc's reported EPS for the quarter was a loss of 38 cents.
* The company reported a quarterly loss of $2.66 million.
* Alzamend Neuro Inc shares had risen by 20.2% this quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 24.4% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is "hold."
Wall Street's median 12-month price target for Alzamend Neuro Inc is $25.00 This summary was machine generated from LSEG data March 25 at 10:32 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jan. 31 2024 -0.32 -0.38 Missed
Oct. 31 2023 -0.67 -0.44 Beat
Jul. 31 2023 -0.52 -0.60 Missed
Apr. 30 2023 -0.67 -0.45 Beat
Comments